- Home
- KPRX vs MTNB Comparison
KPRX vs MTNB Comparison
Compare KPRX & MTNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPRX
- MTNB
- Stock Information
- Founded
- KPRX 1998
- MTNB 2013
- Country
- KPRX United States
- MTNB United States
- Employees
- KPRX N/A
- MTNB N/A
- Industry
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- MTNB Biotechnology: Pharmaceutical Preparations
- Sector
- KPRX Health Care
- MTNB Health Care
- Exchange
- KPRX Nasdaq
- MTNB Nasdaq
- Market Cap
- KPRX 9.2M
- MTNB 10.8M
- IPO Year
- KPRX N/A
- MTNB N/A
- Fundamental
- Price
- KPRX $2.52
- MTNB $1.60
- Analyst Decision
- KPRX Strong Buy
- MTNB Hold
- Analyst Count
- KPRX 1
- MTNB 1
- Target Price
- KPRX $10.00
- MTNB N/A
- AVG Volume (30 Days)
- KPRX 52.9K
- MTNB 38.3K
- Earning Date
- KPRX 11-07-2025
- MTNB 11-12-2025
- Dividend Yield
- KPRX N/A
- MTNB N/A
- EPS Growth
- KPRX N/A
- MTNB N/A
- EPS
- KPRX N/A
- MTNB N/A
- Revenue
- KPRX N/A
- MTNB N/A
- Revenue This Year
- KPRX N/A
- MTNB N/A
- Revenue Next Year
- KPRX N/A
- MTNB N/A
- P/E Ratio
- KPRX N/A
- MTNB N/A
- Revenue Growth
- KPRX N/A
- MTNB N/A
- 52 Week Low
- KPRX $2.21
- MTNB $0.47
- 52 Week High
- KPRX $4.18
- MTNB $3.76
- Technical
- Relative Strength Index (RSI)
- KPRX 42.43
- MTNB 41.02
- Support Level
- KPRX $2.21
- MTNB $1.82
- Resistance Level
- KPRX $2.80
- MTNB $1.93
- Average True Range (ATR)
- KPRX 0.15
- MTNB 0.13
- MACD
- KPRX -0.03
- MTNB -0.04
- Stochastic Oscillator
- KPRX 41.89
- MTNB 16.28
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About MTNB Matinas Biopharma Holdings Inc.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others.